Palatin Technologies Inc - Asset Resilience Ratio
Palatin Technologies Inc (PTN) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Palatin Technologies Inc's Asset Resilience Ratio has changed over time. Check Palatin Technologies Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Palatin Technologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Palatin Technologies Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Palatin Technologies Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Palatin Technologies Inc Industry Peers by Asset Resilience Ratio
Compare Palatin Technologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266 |
Biotechnology | 0.54% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866 |
Biotechnology | 0.29% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Palatin Technologies Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Palatin Technologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.00% | $0.00 | $10.74 Million | -- |
| 2023-06-30 | 61.22% | $10.98 Million | $17.94 Million | -21.78pp |
| 2022-06-30 | 83.00% | $29.94 Million | $36.07 Million | -6.31pp |
| 2021-06-30 | 89.31% | $60.10 Million | $67.30 Million | -8.10pp |
| 2020-06-30 | 97.41% | $82.85 Million | $85.05 Million | +55.87pp |
| 2019-06-30 | 41.54% | $43.51 Million | $104.74 Million | -56.49pp |
| 2018-06-30 | 98.03% | $38.25 Million | $39.02 Million | +26.86pp |
| 2017-06-30 | 71.17% | $40.45 Million | $56.83 Million | +58.68pp |
| 2016-06-30 | 12.49% | $1.38 Million | $11.05 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $29.47 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $12.56 Million | -- |
| 2013-06-30 | 20.94% | $5.25 Million | $25.07 Million | +14.43pp |
| 2012-06-30 | 6.50% | $350.00K | $5.38 Million | -21.44pp |
| 2010-06-30 | 27.95% | $3.46 Million | $12.39 Million | +1.89pp |
| 2009-06-30 | 26.06% | $3.44 Million | $13.20 Million | +8.53pp |
| 2008-06-30 | 17.53% | $3.35 Million | $19.12 Million | +12.10pp |
| 2007-06-30 | 5.43% | $2.32 Million | $42.78 Million | -0.39pp |
| 2006-06-30 | 5.82% | $2.33 Million | $40.05 Million | -0.96pp |
| 2005-06-30 | 6.78% | $2.39 Million | $35.17 Million | -3.33pp |
| 2004-06-30 | 10.11% | $2.47 Million | $24.38 Million | -7.88pp |
| 2003-06-30 | 17.99% | $4.09 Million | $22.72 Million | -6.27pp |
| 2000-06-30 | 24.26% | $2.16 Million | $8.89 Million | +13.62pp |
| 1999-06-30 | 10.64% | $500.00K | $4.70 Million | -- |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more